Prognostic Hemodynamic and Metabolic Profiles of Late Stage Lower Extremity Arterial Disease

University of Tartu750 enrolled

Overview

Late stage lower extremity arterial disease (LEAD) is known to be associated with hemodynamic and metabolic abnormalities and very poor long-term prognosis. The prognostic value of hemodynamic and metabolic profiling, however, is yet to be determined in this patient group. Current study aims to identify novel prognostic biomarkers for better risk stratification of late stage LEAD patients. It also allows to determine associations between hemodynamic/arterial stiffness indices, low-molecular weight metabolites and other substances (e.g. mediators of inflammation and bone-mineral metabolism, cardiac and kidney injury biomarkers, microRNAs) thus providing potentially valuable insight into the pathogenic mechanisms of this disease.

Study Type

OBSERVATIONAL

Enrollment

750

Conditions

Lower Extremity Arterial Disease (Fontaine Stages IIb-IV)

Eligibility

Sex: ALLMin age: 35 YearsMax age: 85 Years

Medical Language ↔ Plain English

Exclusion Criteria: * Fontaine stage I-IIa; * acute limb ischemia; * age \<35 or \>85 years; * fasting \< 6 hours; * time since the last use of tobacco products \< 4 hours; * body mass index ≥ 40 kg/m2 * blood pressure ≥ 180/120mmHg; * unstable angina; * atrial fibrillation at the time of presentation; * myocardial infarction, stroke or TIA during the preceding 3 months; * any revascularization during the preceding 1 month; * severe heart failure (NYHA IV); * clinically significant heart valve disease; * severe physical disability (other than limb ischemia); * acute infectious disease; * active malignancy or chemotherapy or disease-free \< 5 years; * type 1 diabetes; * uncompensated thyrotoxicosis/hypothyroidism or other clinically significant endocrine disorders; * moderate to severe asthma (GINA 2016); * severe chronic obstructive pulmonary disease (mMRC grade 3-4) * acute (KDIGO 2012) or chronic renal disease (eGFR-EPI \<30mL/min/1.73 m2); * clinically significant acute or chronic liver disease; * severe anemia (\<80 g/L); * clinically significant neuroinflammatory or neurodegenerative disease; * active rheumatism; * clinically significant connective tissue disease; * alcoholism or drug abuse; * psychotic disorders

Outcomes

Primary Outcomes

Number of major adverse cardiovascular events, major adverse limb events and deaths

A composite of any of the following events, as documented by patients' hospital or death records: 1. nonfatal myocardial infarction or stroke 2. fatal myocardial infarction or stroke 3. hospitalization for angioplasty or bypass surgery for coronary or peripheral vessel disease 4. LEAD-related major lower extremity amputation 5. other cardiovascular deaths (cardiac arrest, lethal arrhythmia, heart failure, aortic dissection or rupture) 6. non-cardiovascular deaths

Time frame: 5 years

Secondary Outcomes

Number of fatal cardiovascular events

Time frame: 5 years

Number of non-fatal cardiovascular events

Time frame: 5 years

Number of LEAD-related major lower extremity amputations

Time frame: 5 years

Number of hospitalizations for angioplasty or bypass surgery for coronary or peripheral vessel disease

Time frame: 5 years

Number of deaths from all causes

Time frame: 5 years

Prognostic Hemodynamic and Metabolic Profiles of Late Stage Lower Extremity Arterial Disease

Overview

Conditions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes

Central Contacts